Status Epilepticus — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for status epilepticus. 59 active patents protecting 4 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

4
Approved drugs
59
Active US patents
62/100
Avg vulnerability
—
Annual revenue covered

Originators in Status Epilepticus

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Wyeth/Pfizer) 59 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating status epilepticus. Each bar = one year. Y-axis scaled to peak year (16 patents).

6
27
6
28
15
29
8
31
6
32
16
34
2
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Keppra
levetiracetam
 Generic (originally UCB Pharma) 28 56 — 2027-09-03
Valium
diazepam
 Generic (originally Roche) 21 67 — 2029-03-27
Versed
midazolam
 Generic (originally Roche) 6 61 — 2028-01-18
Ativan
lorazepam
 Generic (originally Wyeth/Pfizer) 4 64 — 2034-01-08

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9687495 Versed method of use 75 2028-01-18
9289432 Versed method of use 75 2028-01-18
8217033 Versed method of use 75 2028-01-18
12337061 Valium method of use 75 2032-06-13
12337061 Valium method of use 75 2032-06-13
12337061 Valium method of use 75 2032-06-13
12324852 Valium method of use 75 2032-10-16
12324852 Valium method of use 75 2032-10-16
12324852 Valium method of use 75 2032-10-16
8999393 Ativan method of use 70 2034-01-08

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10966990 Versed formulation 42 2038-06-20
10966990 Versed formulation 42 2038-06-20
11160786 Keppra formulation 42 2034-03-14
11160786 Keppra formulation 42 2034-03-14
11160786 Keppra formulation 42 2034-03-14
11160786 Keppra formulation 42 2034-03-14
8802142 Keppra formulation 53 2031-06-07
8802142 Keppra formulation 53 2031-06-07
8802142 Keppra formulation 53 2031-06-07
8802142 Keppra formulation 53 2031-06-07

Related